Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals OY1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...
Read more
Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patients to undergo...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Data continue to demonstrate prolonged durability of response, with median duration of CR reaching 16.1 months in frontline HR‑MDS, supporting the upcoming initiation of the Phase 2b trialMedian duration of Complete Remission (CR) in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) extended to 16.1 months with bexmarilimab + azacitidineFrontline HR-MDS treatment achieved an 85% Overall...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...
Read more
Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, as announced on 28 May 2026, issued 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds.In total, 21,469,427 new Treasury Shares in the Company have on 8 June 2026 been registered in the Finnish Trade...
Read more
IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia has reached the Company's previously disclosed target enrollment of 146 patients, with 146 participants randomized at baseline. The Company's prior enrollment updates described progress toward this 146-patient target. Based on observed and potential attrition between...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced new clinical data from the BI-1206 triplet combination in relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL) to be presented in a poster at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden.The poster summarizes key efficacy, safety,...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL is being presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden in a poster titled "Targeting TNFR2 with BI-1808 with or...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer:Faron Pharmaceuticals Oy 2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An acquisition or disposal of financial instruments☐ An event changing the breakdown of...
Read more
Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(Nasdaq Stockholm:EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs, today announced the re-airing of a special episode of Behind the Mystery™, a television series featured on The Balancing Act®, which is broadcast nationally in the U.S. on the Lifetime...
Read more
AbTherx, Inc., a privately held biotechnology company focused on accelerating the discovery of next-generation antibody therapeutics, today announced an expansion of its proprietary Atlas™ Mouse technologies and leadership team as it sharpens of its discovery lens towards multispecifics and previously undruggable targets. The company is powering this new phase of growth with an expanded common light chain technology portfolio, a novel VHH...
Read more
IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share. According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress...
Read more
Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing high-potential drug candidates for diseases with significant unmet medical needs through a disciplined pharmaceutical development platform and focused subsidiary companies, today announced that its directors and officers have settled C$1,372,761.20 in accrued management and director fees through the issuance of 12,749,643 common shares of...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares:Faron Pharmaceuticals Oy1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an "X")An acquisition or disposal of shares An...
Read more
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares...
Read more
NGD Infection Prevention announced today that its automated sequence-based infection transmission detection system is now compatible with Oxford Nanopore long-read sequencing. The automation, throughput and simplicity of use of the NGD200 sample preparation robotic system and NGD's integrated automated bioinformatics are now all available for Nanopore sequencing.Infection prevention teams increasingly recognize that comparing the whole genome...
Read moreRegentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout of GelrinC® in Europe, where it has CE Mark approval.The hands-on training program is designed to train...
Read more
Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed by Shanghai Henlius Biotech, Inc.According to communication shared by Henlius, the first patients have now been dosed in all regions participating in the global Phase 3 study of HLX22, including China, Japan, Korea, Latin America, Australia, the United States and Europe.HLX22 is an innovative...
Read more
Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announces that, Nasdaq Helsinki Ltd's Disciplinary Committee has issued their decision and imposed a fine amounting to EUR 30,000 on Faron Pharmaceuticals Oy ("Faron" or "Company") for breaching the Nasdaq First North Growth Rulebook for Issuers of Shares ("Rules") regarding the...
Read more
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical...
Read more
